- Home
- BXP vs ICLR Comparison
BXP vs ICLR Comparison
Compare BXP & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXP
- ICLR
- Stock Information
- Founded
- BXP 1970
- ICLR 1990
- Country
- BXP United States
- ICLR Ireland
- Employees
- BXP N/A
- ICLR N/A
- Industry
- BXP Real Estate Investment Trusts
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BXP Real Estate
- ICLR Health Care
- Exchange
- BXP Nasdaq
- ICLR Nasdaq
- Market Cap
- BXP 13.1B
- ICLR 15.7B
- IPO Year
- BXP 1997
- ICLR 1998
- Fundamental
- Price
- BXP $79.56
- ICLR $203.67
- Analyst Decision
- BXP Buy
- ICLR Strong Buy
- Analyst Count
- BXP 14
- ICLR 10
- Target Price
- BXP $80.64
- ICLR $290.60
- AVG Volume (30 Days)
- BXP 1.3M
- ICLR 2.1M
- Earning Date
- BXP 10-29-2024
- ICLR 10-23-2024
- Dividend Yield
- BXP 4.94%
- ICLR N/A
- EPS Growth
- BXP 87.61
- ICLR 44.49
- EPS
- BXP 2.30
- ICLR 8.99
- Revenue
- BXP $3,344,005,000.00
- ICLR $8,306,823,000.00
- Revenue This Year
- BXP N/A
- ICLR $4.00
- Revenue Next Year
- BXP $1.56
- ICLR $3.16
- P/E Ratio
- BXP $34.54
- ICLR $21.76
- Revenue Growth
- BXP 4.47
- ICLR 3.63
- 52 Week Low
- BXP $52.61
- ICLR $183.38
- 52 Week High
- BXP $90.11
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- BXP 42.93
- ICLR 33.38
- Support Level
- BXP $77.28
- ICLR $183.38
- Resistance Level
- BXP $79.76
- ICLR $217.91
- Average True Range (ATR)
- BXP 2.26
- ICLR 8.19
- MACD
- BXP -0.41
- ICLR 0.24
- Stochastic Oscillator
- BXP 34.18
- ICLR 41.83
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.